Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)Original Article Published on 2023-06-262024-09-05 Journal: American Journal of Respiratory and Critical Care Medicine [Category] update2024, [키워드] COPD dual PDE3 and PDE4 inhibitor ensifentrine nebulized therapy [DOI] 10.1164/rccm.202306-0944OC PMC 바로가기 [Article Type] Original Article